vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and MID PENN BANCORP INC (MPB). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $62.0M, roughly 1.4× MID PENN BANCORP INC). On growth, MID PENN BANCORP INC posted the faster year-over-year revenue change (30.8% vs 17.7%). MID PENN BANCORP INC produced more free cash flow last quarter ($71.8M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 21.1%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Commerce Bancorp was a Cherry Hill, New Jersey–based bank created in 1973. In 2007, it was purchased by Toronto-Dominion Bank, which merged Commerce into TD Banknorth, the latter of which was rebranded to TD Bank.
IOVA vs MPB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $62.0M |
| Net Profit | — | $19.4M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | 43.6% |
| Net Margin | — | 31.4% |
| Revenue YoY | 17.7% | 30.8% |
| Net Profit YoY | — | 47.0% |
| EPS (diluted) | — | $0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $62.0M | ||
| Q3 25 | $67.5M | $61.8M | ||
| Q2 25 | $60.0M | $54.3M | ||
| Q1 25 | $49.3M | $47.7M | ||
| Q4 24 | $73.7M | $47.4M | ||
| Q3 24 | $58.6M | $45.3M | ||
| Q2 24 | $31.1M | $44.1M | ||
| Q1 24 | $715.0K | $42.3M |
| Q4 25 | — | $19.4M | ||
| Q3 25 | $-91.3M | $18.3M | ||
| Q2 25 | $-111.7M | $4.8M | ||
| Q1 25 | $-116.2M | $13.7M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $-83.5M | $12.3M | ||
| Q2 24 | $-97.1M | $11.8M | ||
| Q1 24 | $-113.0M | $12.1M |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | 43.6% | ||
| Q3 25 | -140.7% | 39.3% | ||
| Q2 25 | -189.8% | 7.9% | ||
| Q1 25 | -245.8% | 35.2% | ||
| Q4 24 | -117.5% | 34.1% | ||
| Q3 24 | -152.1% | 32.8% | ||
| Q2 24 | -327.6% | 32.4% | ||
| Q1 24 | -16464.6% | 34.8% |
| Q4 25 | — | 31.4% | ||
| Q3 25 | -135.3% | 29.6% | ||
| Q2 25 | -186.2% | 8.8% | ||
| Q1 25 | -235.5% | 28.8% | ||
| Q4 24 | — | 27.9% | ||
| Q3 24 | -142.7% | 27.1% | ||
| Q2 24 | -312.2% | 26.7% | ||
| Q1 24 | -15800.8% | 28.7% |
| Q4 25 | — | $0.83 | ||
| Q3 25 | — | $0.79 | ||
| Q2 25 | $-0.33 | $0.22 | ||
| Q1 25 | $-0.36 | $0.71 | ||
| Q4 24 | $-0.24 | $0.72 | ||
| Q3 24 | $-0.28 | $0.74 | ||
| Q2 24 | $-0.34 | $0.71 | ||
| Q1 24 | $-0.42 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $814.1M |
| Total Assets | $913.2M | $6.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | — | ||
| Q3 25 | $300.8M | — | ||
| Q2 25 | $301.2M | — | ||
| Q1 25 | $359.7M | — | ||
| Q4 24 | $323.8M | — | ||
| Q3 24 | $397.5M | — | ||
| Q2 24 | $412.5M | — | ||
| Q1 24 | $356.2M | — |
| Q4 25 | $698.6M | $814.1M | ||
| Q3 25 | $702.3M | $796.3M | ||
| Q2 25 | $698.5M | $775.7M | ||
| Q1 25 | $767.9M | $667.9M | ||
| Q4 24 | $710.4M | $655.0M | ||
| Q3 24 | $773.5M | $573.1M | ||
| Q2 24 | $768.5M | $559.7M | ||
| Q1 24 | $680.0M | $551.0M |
| Q4 25 | $913.2M | $6.1B | ||
| Q3 25 | $904.9M | $6.3B | ||
| Q2 25 | $907.4M | $6.4B | ||
| Q1 25 | $966.7M | $5.5B | ||
| Q4 24 | $910.4M | $5.5B | ||
| Q3 24 | $991.1M | $5.5B | ||
| Q2 24 | $964.3M | $5.4B | ||
| Q1 24 | $869.8M | $5.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $80.0M |
| Free Cash FlowOCF − Capex | $-61.9M | $71.8M |
| FCF MarginFCF / Revenue | -71.3% | 115.8% |
| Capex IntensityCapex / Revenue | 10.7% | 13.3% |
| Cash ConversionOCF / Net Profit | — | 4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $132.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $80.0M | ||
| Q3 25 | $-78.7M | $26.3M | ||
| Q2 25 | $-67.4M | $29.0M | ||
| Q1 25 | $-103.7M | $11.5M | ||
| Q4 24 | $-73.3M | $51.4M | ||
| Q3 24 | $-59.0M | $16.9M | ||
| Q2 24 | $-98.4M | $18.0M | ||
| Q1 24 | $-122.3M | $12.4M |
| Q4 25 | $-61.9M | $71.8M | ||
| Q3 25 | $-89.5M | $24.3M | ||
| Q2 25 | $-74.9M | $27.2M | ||
| Q1 25 | $-109.9M | $8.8M | ||
| Q4 24 | $-77.5M | $44.5M | ||
| Q3 24 | $-61.3M | $16.8M | ||
| Q2 24 | $-98.9M | $17.7M | ||
| Q1 24 | $-126.5M | $12.1M |
| Q4 25 | -71.3% | 115.8% | ||
| Q3 25 | -132.7% | 39.4% | ||
| Q2 25 | -124.9% | 50.1% | ||
| Q1 25 | -222.8% | 18.4% | ||
| Q4 24 | -105.1% | 93.8% | ||
| Q3 24 | -104.6% | 37.1% | ||
| Q2 24 | -317.9% | 40.2% | ||
| Q1 24 | -17685.3% | 28.5% |
| Q4 25 | 10.7% | 13.3% | ||
| Q3 25 | 16.1% | 3.1% | ||
| Q2 25 | 12.4% | 3.2% | ||
| Q1 25 | 12.6% | 5.7% | ||
| Q4 24 | 5.7% | 14.6% | ||
| Q3 24 | 3.9% | 0.0% | ||
| Q2 24 | 1.4% | 0.7% | ||
| Q1 24 | 583.4% | 0.8% |
| Q4 25 | — | 4.12× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 6.08× | ||
| Q1 25 | — | 0.84× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | — | 1.37× | ||
| Q2 24 | — | 1.53× | ||
| Q1 24 | — | 1.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
MPB
Segment breakdown not available.
